CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

France's Median Technologies Q3 revenue rises to record high

By Reuters News


Overview

  • France medical imaging firm's Q3 revenue rose 14.4% yr/yr to record €6.7 mln

  • Order backlog hit record €90.9 mln at end-September, up 23.5% yr/yr


Outlook

  • Company expects first eyonis LCS revenues in the first half of 2027

  • Company says cash runway extends through H1 2028, with potential extension to H1 2029 if warrants exercised


Result Drivers

  • LARGE PROJECT WIN - Co secured €8.4 mln global Phase III oncology imaging project, contributing to order backlog and revenue growth

  • BIOPHARMA DEMAND - Sustained demand from biopharma clients drove iCRO business momentum and backlog growth

  • CHINA GROWTH - Revenue growth in H1 2026 mainly driven by China, up 10% yr/yr and accounting for 39% of group revenue


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 6.7 mln

Q3 iCRO Order Backlog

EUR 90.9 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Median Technologies SA is €12.95, about 196.3% above its October 28 closing price of €4.37


Reuters Recommended Reads

  • Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

  • Oct 28 - Joinn Laboratories Q3 revenue rises on industry recovery

  • Oct 27 - Healthcare data firm IQVIA Q3 revenue beats on strong bookings


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.